Search

Your search keyword '"Horr, Samuel"' showing total 27 results
Start Over Author "Horr, Samuel"
27 results on '"Horr, Samuel"'

1. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial.

Author

Jaber, Wissam A., Gonsalves, Carin F., Stortecky, Stefan, Horr, Samuel, Pappas, Orestis, Gandhi, Ripal T., Pereira, Keith, Giri, Jay, Khandhar, Sameer J., Ammar, Khawaja Afzal, Lasorda, David M., Stegman, Brian, Busch, Lucas, Dexter II, David J., Azene, Ezana M., Daga, Nikhil, Elmasri, Fakhir, Kunavarapu, Chandra R., Rea, Mark E., and Rossi, Joseph S.

Published
2025
Full Text
View/download PDF

6. List of Contributors

Author

Abbas, Samer, primary, Abdullah, Shuaib, additional, Ahmad, Hasan, additional, Ailawadi, Gorav, additional, Alkashkari, Wail, additional, Alsanjari, Osama, additional, Anderson, Jason H., additional, Askew, Judah, additional, Asmarats, Luis, additional, Athappan, Ganesh, additional, Attia, Rizwan, additional, Babaliaros, Vasilis, additional, Bae, Richard Y., additional, Baker, Charles M., additional, Banerjee, Subhash, additional, Bapat, Vinayak N., additional, Barker, Colin M., additional, Ben-Dor, Itsik, additional, Bertog, Stefan, additional, Blanke, Phillipe, additional, Block, Peter, additional, Boehm, Patrick, additional, Brecker, Stephen, additional, Brilakis, Emmanouil S., additional, Burns, Marcus, additional, Butter, Christian, additional, Cabalka, Allison K., additional, Cabuay, Barry, additional, Campbell, Alex, additional, Carroll, John D., additional, Cheung, Anson W., additional, Chhatriwalla, Adnan K., additional, Cohen, Martin, additional, Cohen, Mauricio G., additional, Corrigan, Frank, additional, Dowling, Cameron, additional, Dutta, Tanya, additional, Eleid, Mackram, additional, Farivar, Robert Saeid, additional, Feldman, Ted, additional, Flavin, Thomas, additional, Forcillo, Jessica, additional, Franke, Jennifer, additional, Gafoor, Sameer, additional, Girdauskas, Evaldas, additional, Goldberg, Steven L., additional, Gössl, Mario, additional, Guerrero, Mayra, additional, Haak, Alexander, additional, Hague, Cameron, additional, Harmel, Eva, additional, Hijazi, Ziyad, additional, Hildick-Smith, David, additional, Hofmann, Ilona, additional, Horr, Samuel E., additional, Htun, Nay M., additional, Hua (Anthony) Kueh, Shaw, additional, Jelnin, Vladimir, additional, Jones, Brandon M., additional, Joshi, Ravi, additional, Kahwash, Rami, additional, Kalra, Ankur, additional, Kamioka, Norihiko, additional, Kapadia, Samir R., additional, Kaple, Ryan K., additional, Karacsonyi, Judit, additional, Katz, Marc R., additional, Kelly, John J., additional, Kessel, Samuel, additional, Kim, Ung, additional, Kleiman, Neal S., additional, Knickelbine, Thomas, additional, Krishnaswamy, Amar, additional, Kshettry, Vibhu, additional, Kueh, Shaw-Hua, additional, Kuntijoro, Ivandito, additional, Kuwata, Shingo, additional, Leipsic, Jonathon, additional, Lerakis, Stamatios, additional, Lesser, John R., additional, Lilly, Scott M., additional, Lim, D. Scott, additional, Lin, David, additional, Maisano, Francesco, additional, Mann, Gurdeep, additional, Meduri, Christopher, additional, Mick, Stephanie, additional, Mooney, Michael, additional, Myat, Aung, additional, Naidu, Srihari S., additional, Neuss, Michael, additional, Nietlispach, Fabian, additional, Ohana, Mickaël, additional, Parastatidis, Ioannis, additional, Pasala, Tilak K.R., additional, Patel, Ateet, additional, Pearson, Paul, additional, Pedersen, Wesley R., additional, Philippon, François, additional, Pichard, Augusto, additional, Poulose, Anil, additional, Pozzoli, Alberto, additional, Price, Matthew J., additional, Rajagopal, Vivek, additional, Raphael, Claire, additional, Reardon, Michael J., additional, Regar, Evelyn, additional, Rodés-Cabau, Josep, additional, Rogers, Jason H., additional, Ruiz, Carlos E., additional, Salinger, Michael, additional, Saric, Muhamed, additional, Satler, Lowell, additional, Saw, Jacqueline, additional, Schneider, Lynelle, additional, Shah, Atman P., additional, Sharma, Rahul, additional, Sherrid, Mark Victor, additional, Shome, Joy S., additional, Sievert, Horst, additional, Singh, Gagan D., additional, Smith, Thomas W., additional, Sun, Benjamin, additional, Suradi, Hussam, additional, Tang, Gilbert H.L., additional, Taramasso, Maurizio, additional, Thakkar, Jay, additional, Thourani, Vinod H., additional, Tonne, Stacey, additional, Ungi, Imre, additional, Vaskelyte, Laura, additional, Venturini, Joseph M., additional, Vezmar, Marko, additional, Waksman, Ron, additional, Wang, Zuyue, additional, Webb, John Graydon, additional, Wiktor, Dominik M., additional, and Williams, Mathew R., additional

Published
2019
Full Text
View/download PDF

7. IMPACT OF USING HIGH-SENSITIVITY CARDIAC TROPONIN ASSAY ON DISPOSITION OF PATIENTS WITH CHEST PAIN IN THE ED IN A COMMUNITY HOSPITAL SETTING

Author

Ali, Fathi I., primary, Fitzpatrick, Janet, additional, Byram, Mark, additional, Hanna, Lee, additional, Smart, Kristy, additional, Sawalha, Khalid, additional, Jefferson, Brian K., additional, Gage, Ann, additional, Gentry, James L., additional, Horr, Samuel, additional, Amghaiab, Idris Ali, additional, Brewer, Lauren, additional, El-Rifai, Ahmed, additional, Hackett, Mary, additional, Adams, Lydia P., additional, Cobb, Dianna, additional, Nur, Sareda A., additional, Stabile, Michael, additional, and Van Decar, Tama, additional

Published
2023
Full Text
View/download PDF

8. Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement

Author

Kapadia, Samir R., primary, Makkar, Raj, additional, Leon, Martin, additional, Abdel-Wahab, Mohamed, additional, Waggoner, Thomas, additional, Massberg, Steffen, additional, Rottbauer, Wolfgang, additional, Horr, Samuel, additional, Sondergaard, Lars, additional, Karha, Juhana, additional, Gooley, Robert, additional, Satler, Lowell, additional, Stoler, Robert C., additional, Messé, Steven R., additional, Baron, Suzanne J., additional, Seeger, Julia, additional, Kodali, Susheel, additional, Krishnaswamy, Amar, additional, Thourani, Vinod H., additional, Harrington, Katherine, additional, Pocock, Stuart, additional, Modolo, Rodrigo, additional, Allocco, Dominic J., additional, Meredith, Ian T., additional, and Linke, Axel, additional

Published
2022
Full Text
View/download PDF

9. Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement

Author

Kapadia, Samir R., Makkar, Raj, Leon, Martin, Abdel-Wahab, Mohamed, Waggoner, Thomas, Massberg, Steffen, Rottbauer, Wolfgang, Horr, Samuel, Sondergaard, Lars, Karha, Juhana, Gooley, Robert, Satler, Lowell, Stoler, Robert C., Messé, Steven R., Baron, Suzanne J., Seeger, Julia, Kodali, Susheel, Krishnaswamy, Amar, Thourani, Vinod H., Harrington, Katherine, Pocock, Stuart, Modolo, Rodrigo, Allocco, Dominic J., Meredith, Ian T., Linke, Axel, Kapadia, Samir R., Makkar, Raj, Leon, Martin, Abdel-Wahab, Mohamed, Waggoner, Thomas, Massberg, Steffen, Rottbauer, Wolfgang, Horr, Samuel, Sondergaard, Lars, Karha, Juhana, Gooley, Robert, Satler, Lowell, Stoler, Robert C., Messé, Steven R., Baron, Suzanne J., Seeger, Julia, Kodali, Susheel, Krishnaswamy, Amar, Thourani, Vinod H., Harrington, Katherine, Pocock, Stuart, Modolo, Rodrigo, Allocco, Dominic J., Meredith, Ian T., and Linke, Axel

Abstract

BACKGROUND Transcatheter aortic-valve replacement (TAVR) for the treatment of aortic stenosis can lead to embolization of debris. Capture of debris by devices that provide cerebral embolic protection (CEP) may reduce the risk of stroke. METHODS We randomly assigned patients with aortic stenosis in a 1:1 ratio to undergo transfemoral TAVR with CEP (CEP group) or without CEP (control group). The primary end point was stroke within 72 hours after TAVR or before discharge (whichever came first) in the intention-to-treat population. Disabling stroke, death, transient ischemic attack, delirium, major or minor vascular complications at the CEP access site, and acute kidney injury were also assessed. A neurology professional examined all the patients at baseline and after TAVR. RESULTS A total of 3000 patients across North America, Europe, and Australia underwent randomization; 1501 were assigned to the CEP group and 1499 to the control group. A CEP device was successfully deployed in 1406 of the 1489 patients (94.4%) in whom an attempt was made. The incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group (2.3% vs. 2.9%; difference, -0.6 percentage points; 95% confidence interval, -1.7 to 0.5; P = 0.30). Disabling stroke occurred in 0.5% of the patients in the CEP group and in 1.3% of those in the control group. There were no substantial differences between the CEP group and the control group in the percentage of patients who died (0.5% vs. 0.3%); had a stroke, a transient ischemic attack, or delirium (3.1% vs. 3.7%); or had acute kidney injury (0.5% vs. 0.5%). One patient (0.1%) had a vascular complication at the CEP access site. CONCLUSIONS Among patients with aortic stenosis undergoing transfemoral TAVR, the use of CEP did not have a significant effect on the incidence of periprocedural stroke, but on the basis of the 95% confidence interval around this outcome, the results may not rul

Published
2022

20. Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals

Author

Goldenberg, Ilan, Horr, Samuel, Moss, Arthur J., Lopes, Coeli M., Barsheshet, Alon, McNitt, Scott, Zareba, Wojciech, Andrews, Mark L., Robinson, Jennifer L., Locati, Emanuela H., Ackerman, Michael J., Benhorin, Jesaia, Kaufman, Elizabeth S., Napolitano, Carlo, Platonov, Pyotr, Priori, Silvia G., Qi, Ming, Schwartz, Peter J., Shimizu, Wataru, Towbin, Jeffrey A., Vincent, G. Michael, Wilde, Arthur A. M., Zhang, Li, Goldenberg, Ilan, Horr, Samuel, Moss, Arthur J., Lopes, Coeli M., Barsheshet, Alon, McNitt, Scott, Zareba, Wojciech, Andrews, Mark L., Robinson, Jennifer L., Locati, Emanuela H., Ackerman, Michael J., Benhorin, Jesaia, Kaufman, Elizabeth S., Napolitano, Carlo, Platonov, Pyotr, Priori, Silvia G., Qi, Ming, Schwartz, Peter J., Shimizu, Wataru, Towbin, Jeffrey A., Vincent, G. Michael, Wilde, Arthur A. M., and Zhang, Li

Abstract

Objectives This study was designed to assess the clinical course and to identify risk factors for life-threatening events in patients with long-QT syndrome (LQTS) with normal corrected QT (QTc) intervals. Background Current data regarding the outcome of patients with concealed LQTS are limited. Methods Clinical and genetic risk factors for aborted cardiac arrest (ACA) or sudden cardiac death (SCD) from birth through age 40 years were examined in 3,386 genotyped subjects from 7 multinational LQTS registries, categorized as LQTS with normal-range QTc (<= 440 ms [n = 469]), LQTS with prolonged QTc interval (>440 ms [ n = 1,392]), and unaffected family members (genotyped negative with <= 440 ms [ n = 1,525]). Results The cumulative probability of ACA or SCD in patients with LQTS with normal-range QTc intervals (4%) was significantly lower than in those with prolonged QTc intervals (15%) (p < 0.001) but higher than in unaffected family members (0.4%) (p < 0.001). Risk factors ACA or SCD in patients with normal-range QTc intervals included mutation characteristics (transmembrane-missense vs. nontransmembrane or nonmissense mutations: hazard ratio: 6.32; p = 0.006) and the LQTS genotypes (LQTS type 1: LQTS type 2, hazard ratio: 9.88; p = 0.03; LQTS type 3: LQTS type 2, hazard ratio: 8.04; p = 0.07), whereas clinical factors, including sex and QTc duration, were associated with a significant increase in the risk for ACA or SCD only in patients with prolonged QTc intervals (female age >13 years, hazard ratio: 1.90; p = 0.002; QTc duration, 8% risk increase per 10-ms increment; p = 0.002). Conclusions Genotype-confirmed patients with concealed LQTS make up about 25% of the at-risk LQTS population. Genetic data, including information regarding mutation characteristics and the LQTS genotype, identify increased risk for ACA or SCD in this overall lower risk LQTS subgroup. (J Am Coll Cardiol 2011;57:51-9) (C) 2011 by the American College of Cardiology Foundation

Published
2010

23. Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals

Author

Goldenberg, Ilan, primary, Horr, Samuel, additional, Moss, Arthur J., additional, Lopes, Coeli M., additional, Barsheshet, Alon, additional, McNitt, Scott, additional, Zareba, Wojciech, additional, Andrews, Mark L., additional, Robinson, Jennifer L., additional, Locati, Emanuela H., additional, Ackerman, Michael J., additional, Benhorin, Jesaia, additional, Kaufman, Elizabeth S., additional, Napolitano, Carlo, additional, Platonov, Pyotr G., additional, Priori, Silvia G., additional, Qi, Ming, additional, Schwartz, Peter J., additional, Shimizu, Wataru, additional, Towbin, Jeffrey A., additional, Vincent, G. Michael, additional, Wilde, Arthur A.M., additional, and Zhang, Li, additional

Published
2011
Full Text
View/download PDF

26. Total serum bilirubin does not affect vascular reactivity in patients with diabetes.

Author

Susie Yim Yeh, Doupis, John, Rahangdale, Shilpa, Horr, Samuel, Malhotra, Atul, and Veves, Aristidis

Subjects
BILIRUBIN, PEOPLE with diabetes, DIABETES, IONTOPHORESIS, VASODILATION, CARDIOVASCULAR diseases risk factors
Abstract

Bilirubin may have a major role in the prevention of cardiovascular disease based on recent data regarding its anti-oxidant properties. We determined the relationship between total serum bilirubin and vascular reactivity in a large cohort of individuals with diabetes, a disease associated with known oxidant stress. We studied 302 individuals: 52 controls, 37 with type 1 diabetes, 213 with type 2 diabetes. Highresolution ultrasound was used to measure flow-mediated dilation (FMD; endotheliumdependent) and nitroglycerin-induced dilation (NID, endothelium-independent) of the brachial artery. Laser Doppler perfusion imaging was used to measure microvascular reactivity in the forearm skin before and after iontophoresis of acetylcholine (endothelium-dependent) and sodium nitroprusside (endothelium-independent). Bilirubin levels were higher in the type 2 diabetes group (0.71 ± 0.34 mg/dl) compared to controls (0.56 ± 0.26 mg/dl, p < 0.0001). A weak inverse correlation was observed between bilirubin and FMD (r = -0.125, p = 0.032) and skin endothelium-dependent vasodilation (r = -0.157, p = 0.019). In multivariate analyses, however, these correlations were not statistically significant. There is no association between bilirubin levels and vascular reactivity in the macro- and microcirculation of individuals with diabetes. Bilirubin, therefore, does not correlate with predictors of cardiovascular risk in the diabetic population. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

27. Pseudohypoxemia in a Patient With Chronic Lymphocytic Leukemia.

Author

Horr, Samuel, Roberson, Russell, and Hollingsworth, John W.

Subjects
CHRONIC lymphocytic leukemia, CHEST X rays, ECHOCARDIOGRAPHY, OXIMETRY, RESPIRATORY insufficiency, PULSE oximeters, LEUKOCYTE count, DISEASE complications, CANCER risk factors
Abstract

The article discusses the assessment of Pseudohypoxemia in the presence of chronic lymphatic leukemia. It says that Pseudohypoxemia is a phenomenon observed in patients with elevated white blood cell or platelet counts. It tells that pulse oximetry is the most reliable method to clinically assess oxygenation in patients with leukocyte larceny. Moreover, the more accurate measurements of oxygen tension can be attain by minimizing delay in processing arterial sample and preserving sample on ice.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results